other material
confidence high
sentiment positive
materiality 0.70
CervoMed presents new neflamapimod data at AAIC 2026; supports Phase 3 dose 50 mg TID in DLB
CervoMed Inc.
- New analyses from Phase 2b RewinD-LB show neflamapimod slowed worsening in DLB patients with low pTau181 and adequate drug exposure.
- Neflamapimod produced durable slowing of basal forebrain atrophy over 48 weeks and increased basal forebrain connectivity vs placebo.
- Phase 2 study of 80 mg BID met primary safety, tolerability, and PK objectives; encouraging secondary clinical activity findings.
- PK-PD analysis identifies plasma trough threshold ~4 ng/mL; 50 mg TID dose expected to achieve threshold in ~90% of patients.
- Company gained alignment with FDA, EMA, MHRA, and PMDA for planned Phase 3 trial in DLB.